(Stockholm, develops novel drugs to treat heart failure): Has raised 19 MUSD in a funding round from Novo Holdings, Pureos Bioventures, Sound Bioventures, Flerie, Fredrik andAnn-Helene Ljungström alongside Industrifonden with member Peter Wolpert. “We now have the data and funding to accelerate the further clinical development of our first-in-class inotrope to improve the lives of patients with heart failure,” comments Patrik Strömberg, CEO at AnaCardio.

AnaCardio raises 19 MUSD
by
Tags: